Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05945121 · ClinicalTrials.gov registry record · NA
Prehabilitation Program to Improve Cardiac Reserve in High-Risk Patients Undergoing Hematopoietic Stem Cell Transplantation
A NA study of Hematopoietic Stem Cell Transplant, sponsored by University of Michigan Rogel Cancer Center.
- Recruiting
- Registry status
- NA
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT05945121: Recruiting NA study of Hematopoietic Stem Cell Transplant, sponsored by University of Michigan Rogel Cancer Center.
NCT05945121 is a NA study of Hematopoietic Stem Cell Transplant that is actively recruiting participants, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 10 participants, below the 103-participant average among 8 other Hematopoietic Stem Cell Transplant trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05945121, a NA study of Hematopoietic Stem Cell Transplant, is actively recruiting participants, sponsored by University of Michigan Rogel Cancer Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
To assess the feasibility and preliminary effectiveness of a Cardio-Oncology Prehabilitation program in patients at high-risk of developing Cardiovascular (CV) events in improving Cardiorespiratory fitness (CRF) and reducing acute CV complications in Hematopoietic stem cell transplant (HSCT) recipients.
Primary Outcome
Percent of eligible participants who are screened and give informed consent
Conditions Studied
Interventions
- OTHER Cardio-oncology program
Study Locations (1)
Michigan
- University of Michigan Rogel Cancer Center - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2023-08-25 |
| Est. Completion | 2027-08 |
| Phase | NA |
What NCT05945121 shows while recruiting
NCT05945121 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 103-participant average among 8 other Hematopoietic Stem Cell Transplant trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Hematopoietic Stem Cell Transplant appearing as the primary indexed condition, and to 1 intervention - of which Cardio-oncology program is the first listed.
NCT05945121 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT05945121 about?
NCT05945121 is a clinical study titled "Prehabilitation Program to Improve Cardiac Reserve in High-Risk Patients Undergoing Hematopoietic Stem Cell Transplantation". To assess the feasibility and preliminary effectiveness of a Cardio-Oncology Prehabilitation program in patients at high-risk of developing Cardiovascular (CV) events in improving Cardiorespiratory fitness (CRF) and reducing acute CV complications in Hematopoietic stem cell transplant (HSCT) recipie...
What is the current status of trial NCT05945121?
This trial is currently recruiting. It is a NA study. The enrollment target is 10 participants. The study started on 2023-08-25. Estimated completion is 2027-08.
What conditions does trial NCT05945121 study?
This clinical trial studies the following conditions: Hematopoietic Stem Cell Transplant.
What interventions are being tested in trial NCT05945121?
The interventions under investigation include: Cardio-oncology program (OTHER).
Who is sponsoring clinical trial NCT05945121?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05945121 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematopoietic Stem Cell Transplant
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05945121's enrollment target sits among peer trials
10 9th of 8 the lowest of 8 other Hematopoietic Stem Cell Transplant trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hematopoietic Stem Cell Transplant trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Positive Psychology Intervention for Hematopoietic Stem Cell Transplantation Survivors
RECRUITING · NA
-
Coping Skills Training for Symptom Management and Daily Steps (Step Up)
RECRUITING · NA
-
Music Therapy and Hematopoietic Stem Cell Transplant
COMPLETED · NA
-
Vitamin A Replacement in Patients Undergoing HSCT and Its Role on MBI-LCBI Rates
COMPLETED · NA
-
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
RECRUITING · Phase 1
-
T Cell Therapy of Opportunistic Cytomegalovirus Infection
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI